Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study
2007

Effects of Irbesartan on Metabolic Health

Sample size: 3259 publication Evidence: moderate

Author Information

Author(s): Klaus G Parhofer, Felix Münzel, Michael Krekler

Primary Institution: Medical Department II – Grosshadern, University Munich

Hypothesis

Does irbesartan therapy improve metabolic parameters in routine clinical practice?

Conclusion

Irbesartan therapy improves metabolic parameters in routine clinical settings.

Supporting Evidence

  • Irbesartan therapy decreased systolic blood pressure by 14%.
  • Body weight decreased by 2.3% after 6 months of therapy.
  • Fasting glucose levels dropped by 9.5% during the study.
  • LDL-cholesterol levels decreased by 11% after treatment.
  • Triglycerides were reduced by 16% after 6 months.

Takeaway

Taking a medicine called irbesartan can help people with high blood pressure and diabetes feel better by making their blood sugar and cholesterol levels healthier.

Methodology

This was a 6-month, open-label, observational study involving 3259 patients with metabolic syndrome treated with irbesartan.

Potential Biases

Patients included in the study may not represent the general population, leading to potential selection bias.

Limitations

The observational design may introduce bias, and the study-in effect could influence results.

Participant Demographics

The cohort consisted of 64.1% men and 35.9% women, with an average age of 61.5 years.

Statistical Information

P-Value

<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1186/1475-2840-6-36

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication